Satellos Bioscience Inc. (MSLE) Stock Price & Analysis
Satellos Bioscience Inc. (MSLE) closed at USD 6.84 on Thursday, October 15, 2026, up 3.17% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 6.63; the Oct 15, 2026 session ranged USD 6.52–7.06 on volume of 79,931 shares. Market capitalization is $145.12M, with a 52-week range of USD 5.3–13.4 (NGM). Source: Nexqual, retrieved October 16, 2026 at 05:19 UTC.
Also available as compact Markdown for AI agents: nexqual.com/MSLE.md
Key facts (MSLE)
- Analysts: Buy (mean 1.86 on a 1–5 scale) (7 analysts), mean target USD 24.17 (range 16–40).
- Total return with dividends: 1Y +0.0% vs S&P 500 +18.1%; 5Y -54.2% vs S&P 500 +85.1%.
- Next earnings: 2026-11-12, EPS estimate USD -0.63, revenue estimate $0K.
Analysts (MSLE)
Consensus Buy (mean 1.86 on a 1–5 scale), 7 analysts; mean target USD 24.17 (low 16, high 40).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-08 | Craig-Hallum | Initiated | Buy | $24 |
| 2026-08-17 | HC Wainwright & Co. | Reiterated | Buy | $18 |
| 2026-07-09 | HC Wainwright & Co. | Target raised | Buy | $11 → $18 |
Total return (dividends reinvested) (MSLE)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | +0.0% | -54.2% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | +0.0% | -14.4% |
| Volatility (annualized) | 81.5% | 199.5% |
| Max drawdown | -57.0% (Mar 2026→Apr 2026) | -97.6% (Oct 2021→Aug 2022) |
Key Statistics (as of October 16, 2026 at 05:19 UTC)
| Price | USD 6.84 |
|---|---|
| Change | ▲ 3.17% (up) |
| Previous Close | USD 6.63 |
| Open | USD 6.85 |
| Day Range | USD 6.52 – 7.06 |
| 52-Week Range | USD 5.3 – 13.4 |
| Volume | 79,931 shares |
| Market Cap | $145.12M |
| Exchange | NGM |
Technical Analysis (MSLE)
Nexqual's technical model rates MSLE "SELL" based on 1 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:19 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 31.7 (neutral) |
| vs SMA50 | Below (USD 9.01) |
| MACD | -0.62 (negative) |
Analyst Ratings (MSLE)
Wall Street analysts rate MSLE "Buy" based on 7 analysts, with a mean price target of USD 24.17 (range USD 16–40), per Nexqual as of October 16, 2026 at 05:19 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 7 |
| Mean Target | USD 24.17 |
| High Target | USD 40 |
| Low Target | USD 16 |
| Buy / Hold / Sell | 7 / 0 / 0 |
Earnings (MSLE)
| Next Earnings Date | 2026-11-12 |
|---|---|
| EPS Estimate | USD -0.63 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.56 vs est -0.57 ▲ beat |
| 2026-03-31 | USD -0.53 vs est -0.59 ▲ beat |
| 2025-12-31 | USD -0.5 vs est -0.06 ▼ miss |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Financials & Fundamentals (MSLE)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -70.45% |
| Current Ratio | 11.22 |
| Total Cash | $61.84M |
| Total Debt | $0 |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Financial Health Score (MSLE)
Nexqual rates Satellos Bioscience Inc.'s overall financial health "Weak" across five dimensions, as of October 16, 2026 at 05:19 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $62M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$29M (TTM) |
| Efficiency | Critical — ROE -70%, ROA -41.9% |
Ownership (MSLE)
| Insider Ownership | +6.37% |
|---|---|
| Institutional Ownership | +49.70% |
| Shares Outstanding | 21.22M |
| Float | 18.02M |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Leadership (MSLE)
Satellos Bioscience Inc. is led by Francis Gleeson B.B.A. (age 70), Co-Founder, CEO, President & Director, per Nexqual as of October 16, 2026 at 05:19 UTC.
| Co-Founder, CEO, President & Director | Francis Gleeson B.B.A. (age 70) |
|---|---|
| CFO & Corporate Secretary | Elizabeth Williams C.A. (age 47) |
| Chief Scientific Officer | Philip Lambert M.A. (age 56) |
| Senior Vice President of Finance & Administration | J. Robert Hall |
Major Backers & Investors (MSLE)
Notable institutional backers of Satellos Bioscience Inc. include Franklin Resources, Inc., Siren, L.L.C., Vivo Capital, LLC, according to Nexqual as of October 16, 2026 at 05:19 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Franklin Resources, Inc. | 4.42% |
| Siren, L.L.C. | 4.2% |
| Vivo Capital, LLC | 3.84% |
| Point72 Asset Management, L.P. | 3.22% |
| Sphera Funds Management Ltd. | 3.08% |
| Woodline Partners LP | 2.36% |
| Stonepine Capital Management, LLC | 2.32% |
| Montanova Capital LLC | 2.24% |
Source: Nexqual, October 16, 2026 at 05:19 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:19 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt